Back to Publications

Note: The following publications may contain information that is not consistent with the approved prescribing information for resmetirom. These publications do not constitute a recommendation for use outside of country-specific labeling.

Download all
  • Paris MASH 2025 - HEOR
TitleDescriptionDownload
The natural history and clinical progression of MASH in a U.S. adult patient cohort: A claims-based analysis of Optum’s® De-identified Market Clarity Data

Poster Presentation

 DownloadPreview
The Natural History and Economic Burden of Metabolic Dysfunction- associated Steatohepatitis in the US Real-World Setting

Poster Presentation

 DownloadPreview
Relationship-between-non-invasive-tests-clinical-outcomes-and-liver-biopsy-among-people-with-MASH-under-real-world-conditions

Poster Presentation

 DownloadPreview
Real World Semaglutide Dose-Escalation and Persistence among Patients with MASLD

Poster Presentation

 

 DownloadPreview
Real-world clinical characteristics and treatment patterns of patients with metabolic dysfunction-associated steatohepatitis in Germany

Poster Presentation

 DownloadPreview
Real-World clinical characteristics and healthcare resource utilisation of patients with metabolic dysfunction-associated steatohepatitis in Italy

Poster Presentation

 DownloadPreview
Real-World clinical characteristics and healthcare resource utilisation of patients with metabolic dysfunction-associated steatohepatitis in France

Poster Presentation

 

 DownloadPreview
Prevalence and Risk Factors of Liver Fibrosis in a Real World Cohort Data From the German SLD Registry

Poster Presentation

 

 DownloadPreview
Matching-adjusted indirect comparison (MAIC) of resmetirom and semaglutide for patients with metabolic dysfunction-associated steatohepatitis (MASH)

Poster Presentation

 DownloadPreview
Impact of Resmetirom on End-Stage Liver Disease in Noncirrhotic Metabolic-Associated Steatohepatitis (MASH): A Comparative Risk Analysis

Poster Presentation

 DownloadPreview
1 2